Cancer Immunotherapy in Urology, An Issue of Urologic Clinics

The Guest Editors of this issue of Urologic Clinics of North America have compiled a comprehensive collection of articles on urologic cancer immunotherapy, covering personalized vaccines, TCR and dendritic vaccine platforms, neo-adjuvant platforms, immune-editing, and more. The articles provide the most current information needed to improve outcomes in urologic cancer patients.

\n Format: Hardback
\n Length: 240 pages
\n Publication date: 20 October 2020
\n Publisher: Elsevier - Health Sciences Division
\n

The Guest Editors of this issue of Urologic Clinics of North America have assembled a comprehensive collection of articles that provides the most up-to-date knowledge on urologic cancer immunotherapy. Expert authors have contributed clinical review articles on the following topics:

Era of Personalized Vaccines for GU Cancers:
This section explores the development of personalized vaccines tailored to the unique genetic makeup of GU cancers. It discusses the potential benefits of these vaccines in targeting and eliminating cancer cells while minimizing side effects.

TCR and Dendritic Vaccine Platforms for GU Cancers:
This section delves into the use of TCR and dendritic cell vaccine platforms for the treatment of GU cancers. It discusses the mechanisms of action, clinical trials, and potential outcomes of these therapies.

Neo-adjuvant Platforms for GU Cancer Immunotherapy:
This section discusses the role of neo-adjuvant platforms in the treatment of GU cancers. It explores the use of chemotherapy, radiation therapy, or immunotherapy before surgical intervention to enhance the immune response and improve treatment outcomes.

Immune-Editing in Cancer:
This section examines the role of the tumor microenvironment and immune-suppressive pathways in localized and aggressive disease. It discusses the potential of immune-editing therapies, such as CRISPR-Cas9, to target and modify immune cells to enhance cancer treatment.

Clinical Integration of Neo-adjuvant Platforms for Prostate Cancer Immunotherapy:
This section explores the clinical integration of neo-adjuvant platforms for prostate cancer immunotherapy. It discusses the benefits of combining immunotherapy with other treatment modalities, such as hormone therapy or chemotherapy, and the potential for improved treatment outcomes.

Immunotherapy for Muscle and Non-Muscle Invasive Bladder Cancer:
This section discusses the use of immunotherapy for muscle and non-muscle invasive bladder cancer. It explores the use of BCG, checkpoint inhibitors, and other immunotherapeutic agents to improve treatment outcomes and survival rates.

Immunotherapy for Metastatic Bladder Cancer:
This section discusses the use of immunotherapy for metastatic bladder cancer. It explores the use of checkpoint inhibitors, adoptive cell transfer, and other immunotherapeutic agents to target and eliminate cancer cells at metastatic sites.

Immunotherapy Options for Metastatic Castrate-Resistant Prostate Cancer:
This section discusses the immunotherapy options for metastatic castrate-resistant prostate cancer. It explores the use of immune checkpoint inhibitors, CAR-T cells, and other immunotherapeutic agents to target and eliminate cancer cells that have become resistant to conventional treatments.

Role of Tissue-Infiltrating Lymphocytes:
This section examines the role of tissue-infiltrating lymphocytes, particularly TCR, in the treatment of GU cancers. It discusses the mechanisms of action, clinical trials, and potential applications of TCR-based therapies in the treatment of GU cancers.

Therapeutic Platforms for IPSC-Derived CAR-T:
This section discusses the therapeutic platforms for IPSC-derived CAR-T cells. It explores the use of engineered T cells to target and eliminate cancer cells and discusses the potential benefits and challenges of this approach.

Immune-Suppression in Prostate Cancer:
This section examines the underlying causes and influence of immune-suppression in prostate cancer. It discusses the potential of immune-suppressive therapies, such as checkpoint inhibitors, to enhance the immune response and improve treatment outcomes.

Racial Disparity in Response to Immunotherapy:
This section explores the racial disparity in response to immunotherapy in GU cancers. It discusses the potential factors contributing to this disparity and the efforts being made to address it, including the development of targeted therapies and increased access to healthcare.

Urologists who read this issue of Urologic Clinics of North America will gain the most current information they need to improve outcomes in the urologic cancer patient. The articles cover a wide range of topics, from personalized vaccines to immune-editing therapies, and provide a comprehensive understanding of the latest developments in urologic cancer immunotherapy. By staying informed and up-to-date with the latest research and clinical practices, urologists can provide their patients with the best possible care and treatment options.

\n Weight: 458g\n
Dimension: 185 x 262 x 14 (mm)\n
ISBN-13: 9780323754989\n \n